{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:42:25Z","timestamp":1792176145616,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jacc.2020.11.061","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T13:13:18Z","timestamp":1612271598000},"page":"511-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial"],"prefix":"10.1016","volume":"77","author":[{"given":"Tomasz J.","family":"Guzik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinthanie","family":"Ramasundarahettige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Pogosova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Lopez-Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Dyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Muehlhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2020.11.061_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.11.061_bib2","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.11.061_bib3","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/eurheartj\/ehy347","article-title":"Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?","volume":"40","author":"Fox","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.11.061_bib4","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/cvr\/cvz278","article-title":"Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease","volume":"116","author":"Cowie","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2020.11.061_bib5","first-page":"1027","article-title":"Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial","volume":"33","author":"Bosch","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2020.11.061_bib6","doi-asserted-by":"crossref","first-page":"1672f","DOI":"10.1093\/eurheartj\/ehy066","article-title":"Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis","volume":"39","author":"Rocca","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.11.061_bib7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects","volume":"47","author":"Kubitza","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jacc.2020.11.061_bib8","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1111\/jth.14948","article-title":"Fixed dose rivaroxaban can be used in extremes of body weight: a population pharmacokinetic analysis","volume":"18","author":"Speed","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2020.11.061_bib9","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2020.11.061_bib10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/jamacardio.2018.0022","article-title":"Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity","volume":"3","author":"Khan","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2020.11.061_bib11","doi-asserted-by":"crossref","first-page":"3771a","DOI":"10.1093\/eurheartj\/ehz404","article-title":"Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial","volume":"40","author":"de Vries","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.11.061_bib12","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Investigators","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.11.061_bib13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies","volume":"105","author":"Turpie","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2020.11.061_bib14","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.annemergmed.2010.01.002","article-title":"The importance of \"shrinkage\" in subgroup analyses","volume":"55","author":"Lipsky","year":"2010","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jacc.2020.11.061_bib15","first-page":"1","article-title":"Bayesian random-effects meta-analysis using the bayesmeta R package","volume":"93","author":"Roever","year":"2020","journal-title":"J Stat Software"},{"key":"10.1016\/j.jacc.2020.11.061_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0197-2456(90)90030-6","article-title":"Empirical Bayes estimates of subgroup effects in clinical trials","volume":"11","author":"Davis","year":"1990","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jacc.2020.11.061_bib17","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/sim.5543","article-title":"Empirical shrinkage estimator for consistency assessment of treatment effects in multi-regional clinical trials","volume":"32","author":"Quan","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2020.11.061_bib18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ajcn\/68.4.899","article-title":"Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary","volume":"68","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacc.2020.11.061_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.11.061_bib20","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1093\/cvr\/cvz170","article-title":"The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era","volume":"115","author":"Kaplovitch","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2020.11.061_bib21","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"Upreti","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2020.11.061_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.11.061_bib23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH16-02-0087","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT\/PE studies","volume":"116","author":"Di Nisio","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2020.11.061_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjcard.2020.04.016","article-title":"Non-Vitamin K Antagonist oral anticoagulant for atrial fibrillation in obese patients","volume":"127","author":"Wang","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.11.061_bib25","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/cvr\/cvx106","article-title":"The molecular mechanisms of obesity paradox","volume":"113","author":"Antonopoulos","year":"2017","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2020.11.061_bib26","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/cvr\/cvz068","article-title":"Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity","volume":"115","author":"Bonacina","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2020.11.061_bib27","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/cvr\/cvz146","article-title":"Pentraxin 3: a novel target in the obesity-inflammation cascade","volume":"115","author":"Vyas","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2020.11.061_bib28","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A\u00a0comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.11.061_bib29","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/eurheartj\/ehy057","article-title":"The impact of confounding on the associations of different adiposity measures with the incidence of cardiovascular disease: a cohort study of 296 535 adults of white European descent","volume":"39","author":"Iliodromiti","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.11.061_bib30","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1093\/cvr\/cvz241","article-title":"A\u00a0look back: the quest for thrombosis in heart failure continues after COMMANDER HF","volume":"115","author":"Filippatos","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2020.11.061_bib31","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.amjcard.2017.03.028","volume":"119","author":"Balla","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.11.061_bib32","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamacardio.2016.1829","article-title":"Apixaban 5\u00a0mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial","volume":"1","author":"Alexander","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2020.11.061_bib33","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIRCULATIONAHA.118.037955","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight","volume":"139","author":"Hohnloser","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.11.061_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archinte.165.1.55","article-title":"The obesity paradox: body mass index and outcomes in patients with heart failure","volume":"165","author":"Curtis","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2020.11.061_bib35","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1093\/eurheartj\/ehaa293","article-title":"Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial","volume":"41","author":"Doehner","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.11.061_bib36","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1161\/STROKEAHA.111.000069","article-title":"Obesity and the risk of intracerebral hemorrhage: the multicenter study on cerebral hemorrhage in Italy","volume":"44","author":"Pezzini","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2020.11.061_bib37","article-title":"Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease","author":"Liang","year":"2020","journal-title":"Cardiovasc Res"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109720380049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109720380049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:37:39Z","timestamp":1760017059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109720380049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0735109720380049"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2020.11.061","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2020.11.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}